Limb-Girdle Muscular Dystrophy (LGMD) Type 1A: MYOT Gene Sequencing

Test Code: STTID
Turnaround time: 4 weeks
CPT Codes: 81479 x1

Condition Description

Limb-girdle muscular dystrophy (LGMD) is a descriptive term applied to a clinically and genetically heterogeneous group of childhood- or adult-onset muscular dystrophies. LGMD is characterized by weakness and wasting restricted to the limb musculature, proximal greater than distal. Most individuals with LGMD show relative sparing of the heart and bulbar muscles, although exceptions occur, depending on the genetic subtype. Onset, progression, and distribution of the weakness and wasting vary considerably among individuals and genetic subtypes. Serum creatine kinase (CK) levels in individuals with LGMD are usually elevated, and muscle biopsy reveals dystrophic changes. Immunohistochemistry (IHC) testing of a muscle biopsy sample can be used to determine the presence or absence of specific proteins, and confirmatory genetic testing is available in some cases. LGMDs are distinct from the much more common X-linked dystrophinopathies, which include Duchenne and Becker muscular dystrophy (DMD/BMD).

LGMD 1A, also referred to as myotilinopathy, has an average age of onset of 27 years. Symptoms include mild proximal muscle weakness beginning in the hip girdle region and later progressing to the shoulder girdle region. Distal muscle weakness may occur later. Other symptoms can include tight Achilles tendons, nasal speech, and reduced knee and elbow tendon reflexes. LGMD 1A is slowly progressive, and lacks cardiac involvement. Serum CK levels are normal to mildly elevated, and myotilin IHC is normal. LGMD 1A is inherited in an autosomal dominant manner.

Mutations in the MYOT gene cause LGMD 1A. Mutations in the MYOT gene have also been reported in myofibrillar myopathy, which is characterized by slowly progressive weakness that can involve both proximal and distal muscles, and in spheroid body myopathy.

For patients with suspected LGMD 1A, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.


References:


Genes

**MYOT**

Indications

This test is indicated for:

- Confirmation of a clinical diagnosis of LGMD 1A.

Methodology

PCR amplification of 10 exons contained in the MYOT gene is performed on the patient's genomic DNA. Direct sequencing of amplification products is performed in both forward and reverse directions, using automated fluorescence dideoxy sequencing methods. The patient's gene sequences are then compared to a normal reference sequence. Sequence variations are classified as mutations, benign variants unrelated to disease, or variations of unknown clinical significance. Variants of unknown clinical significance may require further studies of the patient and/or family members. This assay does not interrogate the promoter region, deep intronic regions, or other regulatory elements, and does not detect large deletions.

Analytical Sensitivity: ~99%

Specimen Requirements

Submit only 1 of the following specimen types

* Preferred specimen type: Whole Blood

Type: Whole Blood

Specimen Requirements:

In EDTA (purple top) tube:
Infants (2 years): 3-5 ml

Disclaimer: This information is confidential and subject to change without notice. It may not be reproduced in whole or part unless authorized in writing by an authorized EGL representative.
Older Children & Adults: 5-10 ml

Specimen Collection and Shipping: Refrigerate until time of shipment. Ship sample within 5 days of collection at room temperature with overnight delivery.

**Type: Saliva**

**Specimen Requirements:**

Oragene™ Saliva Collection kit (available through EGL) used according to manufacturer instructions.

Specimen Collection and Shipping: Store sample at room temperature. Ship sample within 5 days of collection at room temperature with overnight delivery.

### Special Instructions

Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.

Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.

### Related Tests

- Deletion/duplication analysis of the **MYOT** gene by CGH array is available for those individuals in whom sequence analysis is negative.
- A **LGMD sequencing panel**.
- **Custom diagnostic mutation analysis (KM)** is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to individuals who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.